Effects of weight loss on heart health in obese patients with heart failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how weight loss impacts individuals with heart failure with preserved ejection fraction (HFpEF) who are overweight or obese. Participants will be randomly assigned to either a diet intervention or a control group receiving standard care. The study will assess various outcomes, including heart function, quality of life, and exercise capacity through a series of measurements such as echocardiograms, MRIs, and questionnaires. The study aims to determine if weight loss can improve heart shape and pumping efficiency in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Heart failure with preserved ejection fraction (HFpEF)
* Left ventricular ejection fraction (LVEF) =/\> 50%
* Body Mass Index (BMI) approximately =/\> 27.5 kg/m\^2

Exclusion Criteria:

* Contraindications to magnetic resonance imaging
* NYHA class IV
* Significant valvular, ischemic, infiltrative or other potentially confounding cardiac disease
* Pregnancy, planned pregnancy or lactating
* Any other conditions which may potentially compromise the safety or scientific validity of the study

Where it's running

• Oxford Centre for Clinical Magnetic Resonance Research, John Radcliffe Hospital
  Oxford, United Kingdom Recruiting

Study contacts

• Principal investigator: Oliver J Rider, DPhil — University of Oxford
• Study coordinator: Jiliu Pan, BMBCh
• Email: jiliu.pan@cardiov.ox.ac.uk
• Phone: +44(0)1865234591

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Incretin therapy with tirzepatide for obesity-related HFpEF

  A 15-month study will test whether tirzepatide helps people with obesity and HFpEF by reducing plasma volume.

  Recruiting Phase 4 Columbia University · New York, New York · NCT07554638

• Maridebart cafraglutide for people with obesity and preserved or mildly reduced ejection fraction heart failure

  This trial will test whether adding maridebart cafraglutide to usual heart-failure care can reduce hospital visits, cardiovascular deaths, and improve symptoms in adults with obesity and HFpEF or HFmrEF.

  Recruiting at 651 sites Phase 3 Amgen · Birmingham, Alabama and 685 other locations · NCT07037459

• Improving breathing and exercise capacity in heart failure patients with obesity

  This study is testing if breathing a special helium-oxygen gas mixture can help people with heart failure and obesity breathe better and exercise more easily.

  Recruiting University of Texas Southwestern Medical Center · Dallas, Texas · NCT05723679

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.